摘要
子宫内膜癌是最常见的女性生殖系统肿瘤之一,其亚型非雌激素依赖型(Ⅱ型)子宫内膜癌通常与P53基因突变和HER-2过量表达等基因异常相关。分子靶向治疗有望改善Ⅱ型子宫内膜癌的治疗效果和预后情况。
Endometrial carcinoma (EC) is one of the most common gynecological cancer.Its subtype non-estrogen-dependent endometrial carcinoma (type Ⅱ) is usually associated with gene abnormalities such as P53 gene mutation and HER-2 overexpression.Molecular targeted therapy may improve the therapeutic effect and prognosis of type Ⅱ endometrial carcinoma.
作者
吴海芳
孟祥玉
许恒毅
傅芬
WU Hai-fang;MENG Xiang-yu;XU Heng-yi;FU Fen(Department of Gynecology,the Second Affiliated Hospital of Nanchang University,Nanchang 330006;National Key Laboratory of Food Science and Technology,Nanchang University,Nanchang 330047,China)
出处
《基础医学与临床》
CSCD
2019年第2期277-280,共4页
Basic and Clinical Medicine
基金
江西省自然科学基金重点项目(2016 1ACB20022)
关键词
Ⅱ型子宫内膜癌
基因突变
靶向治疗
type Ⅱ endometrial carcinoma
gene mutation
targeted therapy
